• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy.

作者信息

Eskander Ramez, Lee Jung-Yun, Mirza Mansoor, Lorusso Domenica, Mackay Helen, Ray-Coquard Isabelle, Oaknin Ana, Gonzalez-Martin Antonio, Hasegawa Kosei, Corr Bradley, Wu Xiaohua, Leary Alexandra, Hu Tianle, Dutta Lea, Okpara Chinyere, McKenzie Jodi, Makker Vicky

机构信息

1Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Diego, Moores Cancer Center, La Jolla, CA.

2Yonsei Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

出版信息

J Natl Compr Canc Netw. 2025 Mar 28;23(3.5):TIP25-243. doi: 10.6004/jnccn.2024.7252.

DOI:10.6004/jnccn.2024.7252
PMID:40157347
Abstract
摘要

相似文献

1
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy.
J Natl Compr Canc Netw. 2025 Mar 28;23(3.5):TIP25-243. doi: 10.6004/jnccn.2024.7252.
2
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.一项随机研究，评估E7386联合乐伐替尼的最佳剂量、疗效和安全性，对比在先前接受铂类化疗和免疫检查点抑制剂治疗的晚期/复发性子宫内膜癌中医生选择的治疗方案。
Int J Gynecol Cancer. 2025 Sep;35(9):101812. doi: 10.1016/j.ijgc.2025.101812. Epub 2025 Apr 5.
3
Efficacy and safety of anti-PD-1 monotherapy anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience.抗程序性死亡蛋白1（PD-1）单药治疗、抗PD-1抗体联合乐伐替尼治疗晚期肝细胞癌患者的疗效和安全性：一项真实世界研究。
Ther Adv Med Oncol. 2023 Oct 24;15:17588359231206274. doi: 10.1177/17588359231206274. eCollection 2023.
4
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.研究 309/KEYNOTE-775 中东亚亚组分析：仑伐替尼联合帕博利珠单抗对比既往治疗的晚期或复发性子宫内膜癌患者的医生选择化疗的治疗。
J Gynecol Oncol. 2024 Mar;35(2):e40. doi: 10.3802/jgo.2024.35.e40. Epub 2024 Jan 19.
5
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.帕博利珠单抗联合仑伐替尼对比化疗用于晚期或复发性子宫内膜癌一线治疗的 III 期、随机、开放标签研究：ENGOT-en9/LEAP-001。
Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19.
6
Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study.低剂量仑伐替尼联合抗程序性细胞死亡蛋白-1 治疗在经过大量预处理的复发性卵巢和子宫内膜癌患者中的应用：一项初步研究。
Int J Gynecol Cancer. 2024 Aug 5;34(8):1203-1210. doi: 10.1136/ijgc-2024-005331.
7
Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis.仑伐替尼联合帕博利珠单抗治疗晚期和复发性子宫内膜癌患者的疗效和安全性：系统评价和荟萃分析。
Front Immunol. 2024 Aug 9;15:1404669. doi: 10.3389/fimmu.2024.1404669. eCollection 2024.
8
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者：一项多中心、开放标签、单臂、2 期临床试验的中期分析。
Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25.
9
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.帕博利珠单抗联合推荐起始剂量或降低起始剂量仑伐替尼治疗复发性子宫内膜癌的毒性和疗效。
Gynecol Oncol. 2021 Jul;162(1):24-31. doi: 10.1016/j.ygyno.2021.04.034. Epub 2021 May 3.
10
Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition.进展为双重免疫治疗后的免疫治疗：帕博利珠单抗和乐伐替尼与转移性黑色素瘤患者在PD-1/CTLA-4抑制失败后接受的传统化疗对比
Front Oncol. 2024 Oct 7;14:1420879. doi: 10.3389/fonc.2024.1420879. eCollection 2024.

引用本文的文献

1
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.化疗治疗晚期或复发性子宫内膜癌的临床结局：一项法国观察性回顾性队列研究：ENDOVIE研究
BMJ Open. 2025 Sep 4;15(9):e096837. doi: 10.1136/bmjopen-2024-096837.